Flurbiprofen
Active ingredient · 4 therapeutic classes
Sold as STREFEN HONEY AND LEMON
- Drug class
- Propionic Acid Derivatives
- Availability
- Prescription only
- Routes
- Oral, Ophthalmic
- Markets covered
- 3
- Products on record
- 15
Overview
Plain-language summary, compiled from the cited regulatory records
Flurbiprofen is a medication belonging to the drug class of propionic acid derivatives [1]. It is approved for use in ophthalmic solutions [1].
The approved indication for flurbiprofen sodium ophthalmic solution is the inhibition of intraoperative miosis [1]. This means it is used during eye surgery to prevent the pupil from constricting [1].
Flurbiprofen is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 12 | May 29, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
| US United States | FDA | 1 | July 24, 2024 |
GBUnited Kingdom· MHRA
12 products
Uses
75 mg lozenges are indicated for the short-term symptomatic relief of sore throat in adults and adolescents over the age of 12 years.
How to take
CACanada· Health Canada
2 products
How to take
4 Geriatrics 03/2022 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. 9
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Flurbiprofen sodium ophthalmic solution is indicated for the inhibition of intraoperative miosis.
How to take
Drug interactions
Known interactions involving Flurbiprofen. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 331. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL579800003 · revised June 17, 2025
- [2]Health Canada (DPD) · 01912038 · revised March 22, 2025
- [3]FDA DailyMed · 11db354f-caf9-45… · revised July 24, 2024 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.